Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated September 6, 2022, reports a regulatory update regarding the US Food and Drug Administration (FDA) review of daprodustat. The filing focuses on the potential treatment of anaemia due to chronic kidney disease (CKD) in adult patients, both on and not on dialysis.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory update and does not contain financial performance data.
Material Changes and Regulatory Status
- FDA Advisory Committee: The FDA will convene the Cardiovascular and Renal Drugs Advisory Committee on October 26, 2022, to review the New Drug Application (NDA) for daprodustat.
- Global Regulatory Progress:
- Japan: Duvroq (daprodustat) tablets were approved by the Ministry of Health, Labour and Welfare in June 2022 for renal anaemia.
- Europe: The European Medicines Agency validated the marketing authorisation application in March 2022; it remains under review.
- Clinical Trial Results: The ASCEND phase III programme, involving over 8,000 patients, demonstrated that daprodustat improved or maintained haemoglobin levels within the target range (10-11.5 g/dL). Primary safety analysis showed non-inferiority of major adverse cardiovascular events (MACE) compared to standard of care (erythropoietin stimulating agents) in both dialysis and non-dialysis settings.
Outlook, Risks, and Management Commentary
Management, represented by Chris Corsico (Senior Vice President, Development), expressed commitment to working with the FDA to bring daprodustat to patients, citing the lack of current oral treatment options for anaemia of CKD. The company anticipates additional regulatory submissions throughout 2022.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in the 2021 Form 20-F, Q2 2022 results, and the ongoing impacts of the COVID-19 pandemic.
Key Facts for Investor Verification
- Confirm the outcome of the FDA Advisory Committee meeting scheduled for October 26, 2022.
- Monitor the status of the European Medicines Agency review following the March 2022 validation.
- Verify commercial launch timelines and market access strategies for daprodustat in the US and Europe following potential approvals.
- Review the full ASCEND clinical trial data published in the New England Journal of Medicine for long-term safety and efficacy details.